The invention relates to compound characterized by a general formula (1),
wherein n of R1n is 0, 1, 2, 3 or 4, in particular n of R1n is 0 or 1, and each R1 independently from any other R1 is C1-C3 alkyl, C1-C3 haloalkyl or C1-C3 alkoxy, and DA is a Donor-Acceptor group. The invention relates further to a compound or a pharmaceutical preparation for use in a method for treatment of cancer or intraocular neovascular syndromes.
Two novel quinoxaline-based EphA3 tyrosine kinase inhibitors have been designed and characterized in vivo in a relevant lymphoma model, showing high efficacy in the control of tumor size.
KOZYNCHENKO A. P.; BABICHEV F. S.; PROMONENKOV V. K.; ZUBENKO A. I.; SAVR+, YKP. XIM. ZH., 53,(1987) N 4, 401-404
作者:KOZYNCHENKO A. P.、 BABICHEV F. S.、 PROMONENKOV V. K.、 ZUBENKO A. I.、 SAVR+
DOI:——
日期:——
[EN] 2-AMINO-1-(O-TOLYL)PYRROLO[3,2-B]QUINOXALINE-3-CARBOXAMIDE DERIVATES<br/>[FR] DÉRIVÉS DE 2-AMINO-1-(O-TOLYL)PYRROLO[3,2-B]QUINOXALINE-3-CARBOXAMIDE
申请人:UNIV ZUERICH
公开号:WO2015144923A1
公开(公告)日:2015-10-01
The invention relates to a compound characterized by a general formula (1), wherein R1 is OH or CH2OH. The invention relates further to a pharmaceutical preparation comprising at least one of said compounds. A further aspect of the invention the use of said compound or said pharmaceutical preparation in a method of treatment of disease, in particular the treatment of cancer or intraocular neovascular syndromes.
The invention relates to compound characterized by a general formula (1), wherein n of R1n is 0, 1, 2, 3 or 4, in particular n of R1n is 0 or 1, and each R1 independently from any other R1 is C1-C3 alkyl, C1-C3 haloalkyl or C1-C3 alkoxy, and DA is a Donor-Acceptor group. The invention relates further to a compound or a pharmaceutical preparation for use in a method for treatment of cancer or intraocular neovascular syndromes.